Yamanouchi Pharmaceutical Company Ltd.

Hiroshi Gushima

Toshio Sasaki

Takashi Osono

Shunichi Watanabe

Yoshihiko Oka

Takeshi Saito

Hiroshi Yamaguchi

Keisuke Murakami

Isao Takahashi

Hideo Eiki

Toshiaki Miyoshi

Shuichi Takamura

Kiyoshi Susaki

Makoto Takayama

Toshiyuki Takemoto

Yasushi Kawauchi

Kimio Katsuta

Masao Kato

Masami Yokota

The present invention relates to improved plasminogen activators (improved t-PA) which have a prolonged biological half life, an increased stability to heat and acids and can be expected to be effective as inhibiting inflammation around the site in which thrombus is formed.

Tissue plasminogen activator and method of use

The 7-methoxy-3-heterocyclic thiomethyl cephalosporin derivative possessing excellent antimicrobial activity represented by the general formula ##STR1## wherein R.sup.1 represents ##STR2## group or HOOC-- group, R.sup.2 represents a nitrogen-containing heterocyclic group, and M represents a hydrogen atom or a cation residue forming a salt.

7-methoxy cephalosporin derivative

7.alpha.-Methoxy-3-p-sulfooxy or p-hydroxycinnamoyloxymethyl cephalosporin derivatives which are useful as antibiotics and as intermediates for the production of other 7.alpha.-methoxycephalosporin derivatives.

Process for the production of 7.alpha.-methoxycephalosporin derivatives

7.alpha.-Methoxycephalosporin derivatives

7-Methoxy cephalosporins and process of producing them

A new antibiotic substance, designated Y-G19ZD3, is produced by the fermentation of a newly discovered microorganism Streptomyces organonensis Y-G19Z or a mutant thereof. The antibiotic substance Y-G19ZD3 is effective against gram negative bacteria and is useful also as an intermediate for the production of other antibiotics.

Antibiotic Y-G19Z D3 and the production thereof

Growing community of inventors

Ageo, Japan

Hiroshi Gushima